Autolus Limited
Clinical trials sponsored by Autolus Limited, explained in plain language.
Clinical-stage biopharmaceutical company developing CAR-T cell therapies.
Not investment advice. Company information is shown for context only. Clinical trials frequently fail.
Advertising disclosure. Links marked "(ad)" go to partners we have a commercial relationship with, either a broker where you can trade or a stock-research service, and we may earn a commission if you open an account or subscribe. This never affects what is shown here.
Upcoming readouts
Trials from this sponsor expected to report results within the next 12 months.
- Engineered immune cells take on lupus in first human test Results expected Sep 2027 (estimated)
-
Engineered immune cells take on childhood blood cancers in early trial
Disease control Recruiting nowThis early-phase trial is testing a new CAR T-cell therapy called AUTO1 (obe-cel) in up to 30 children with B-cell acute lymphoblastic leukemia or B-cell non-Hodgkin lymphoma that has returned or not responded to treatment. The therapy uses the child's own immune cells, which are…
Phase 1 • Sponsor: Autolus Limited • Aim: Disease control
Last updated Sep 18, 2026 00:00 UTC
-
Could a single infusion of modified immune cells tame lupus kidney flares?
Disease control Recruiting nowThis study tests a one-time treatment called Obe-cel, made from a patient's own immune cells, for severe lupus nephritis that hasn't improved with standard care. About 35 people aged 12 to 65 will receive the infusion and be monitored for up to 24 months. The main goal is to see …
Phase 2 • Sponsor: Autolus Limited • Aim: Disease control
Last updated Aug 26, 2026 00:00 UTC
-
Could CAR T-Cells halt progressive MS? early trial launches
Disease control Recruiting nowThis early-stage trial is testing a new treatment called obe-cel, a type of cell therapy (CAR T-cell), for people with progressive multiple sclerosis (MS) that hasn't improved with standard treatments. The main goal is to see if it's safe, but researchers will also look for any s…
Phase 1 • Sponsor: Autolus Limited • Aim: Disease control
Last updated Jun 27, 2026 12:00 UTC
-
Last-Resort leukemia treatment made available through expanded access program
Disease control Expanded accessThis expanded access program provides an experimental CAR-T cell therapy called obe-cel to adults with relapsed or refractory B-cell acute lymphoblastic leukemia (ALL) who have no other treatment options. The therapy is made from the patient's own blood cells but did not meet com…
Sponsor: Autolus Limited • Aim: Disease control
Last updated Jun 27, 2026 09:08 UTC